Clinical Trials Browser

Phase 2 × cabiralizumab × Lymphoid × Clear all

NCT03927105 2024-03-18

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Completed

4 enrolled 11 charts

Lymphoma, T-Cell, Peripheral